

GLAXOSMITHKLINE PLC  
Form 6-K  
September 12, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 12 September 2018

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley  
Chief Executive Officer
  - b) Position/status
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument ('Ordinary Shares')  
ISIN: GB0009252882  
Acquisition of Ordinary Shares under the Company's Share Reward Plan.
  - b) Nature of the transaction
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£14.9717	8 (partnership shares)
£14.9717	8 (matching shares)
  - d) Aggregated information  
Aggregated volume Price  
16 Ordinary Shares  
£14.9717
  - e) Date of the transaction 2018-09-11
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R G Connor
  - b) Position/status President, Global Vaccines
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£14.9717	8 (partnership shares)
	£14.9717	8 (matching shares)
d) Aggregated information		
Aggregated volume	16 Ordinary Shares	
Price	£14.9717	
e) Date of the transaction	2018-09-11	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S Dingemans
b) Position/status	Chief Financial Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
	ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£14.9717	8 (partnership shares)
	£14.9717	8 (matching shares)
d) Aggregated information		
Aggregated volume		
Price		

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

16 Ordinary Shares  
£14.9717

- e) Date of the transaction 2018-09-11  
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
a) Name Mr N Hirons  
b) Position/status SVP, Global Ethics & Compliance  
c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

- c) Price(s) and volume(s)  
Price(s) Volume(s)  
£14.9717 8 (partnership shares)  
£14.9717 8 (matching shares)

- d) Aggregated information  
Aggregated volume Price 16 Ordinary Shares  
£14.9717

- e) Date of the transaction 2018-09-11  
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')  
a) Name Mr L Miels  
b) Position/status President, Global Pharmaceuticals  
c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£14.9717	8 (partnership shares)
£14.9717	8 (matching shares)
  - d) Aggregated information
 

Aggregated volume	16 Ordinary Shares
Price	£14.9717
  - e) Date of the transaction 2018-09-11
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D S Redfern
  - b) Position/status Chief Strategy Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share

Reward Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£14.9717	8 (partnership shares)
	£14.9717	8 (matching shares)
Aggregated information		
d) Aggregated volume Price		16 Ordinary Shares £14.9717
e) Date of the transaction		2018-09-11
f) Place of the transaction		London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')		
a) Name		Mr R Simard
b) Position/status		President, Pharmaceutical Supply Chain

c) Initial notification/ amendment		Initial notification
---------------------------------------	--	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name		GlaxoSmithKline plc
b) LEI		5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument		Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--	--

b) Nature of the transaction		Acquisition of Ordinary Shares under the Company's Share Reward Plan.
------------------------------	--	---

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£14.9717	9 (partnership shares)
	£14.9717	9 (matching shares)

Aggregated information		
d) Aggregated volume Price		18 Ordinary Shares £14.9717

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- e) Date of the transaction 2018-09-11  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas  
 b) Position/status SVP, Human Resources  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- Ordinary shares of 25 pence each ('Ordinary Shares')  
 a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £14.9717 8 (partnership shares)  
 £14.9717 8 (matching shares)

Aggregated information

- d) Aggregated volume Price  
 16 Ordinary Shares  
 £14.9717

- e) Date of the transaction 2018-09-11  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson  
 b) Position/status President, Global Affairs  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each  
('Ordinary Shares')  
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction  
Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s)  
Price(s) Volume(s)  
£14.9717 8 (partnership shares)  
£14.9717 8 (matching shares)

d) Aggregated information  
Aggregated volume Price

16 Ordinary Shares  
£14.9717

e) Date of the transaction

2018-09-11

f) Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mrs V A Whyte  
b) Position/status Company Secretary  
c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each  
('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share

Reward Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£14.9717	8 (partnership shares)
	£14.9717	8 (matching shares)
d) Aggregated information		
Aggregated volume Price		16 Ordinary Shares
	£14.9717	
e) Date of the transaction		2018-09-11
f) Place of the transaction		London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: September 12, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc